Relevant bibliographies by topics / Drug-sparing regimen

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters

Academic literature on the topic 'Drug-sparing regimen'

Author: Grafiati
Published: 8 June 2024
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Drug-sparing regimen.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Drug-sparing regimen"

1

Rosa, Rossana, Jose F. Suarez, Marco A. Lorio, et al. "Impact of antiretroviral therapy on clinical outcomes in HIV+ kidney transplant recipients: Review of 58 cases." F1000Research 5 (December 21, 2016): 2893. http://dx.doi.org/10.12688/f1000research.10414.1.

Full text
Abstract:
Background: Antiretroviral therapy (ART) poses challenging drug-drug interactions with immunosuppressant agents in transplant recipients. We aimed to determine the impact of specific antiretroviral regimens in clinical outcomes of HIV+ kidney transplant recipients. Methods: A single-center, retrospective cohort study was conducted at a large academic center. Subjects included 58 HIV- to HIV+ adult, first-time kidney transplant patients. The main intervention was ART regimen used after transplantation. The main outcomes assessed at one- and three-years were: patient survival, death-censored gra
APA, Harvard, Vancouver, ISO, and other styles
2

Dutta, Noton K., Abdullah Alsultan, Thomas J. Gniadek, et al. "Potent Rifamycin-Sparing Regimen Cures Guinea Pig Tuberculosis as Rapidly as the Standard Regimen." Antimicrobial Agents and Chemotherapy 57, no. 8 (2013): 3910–16. http://dx.doi.org/10.1128/aac.00761-13.

Full text
Abstract:
ABSTRACTStrategies involving new drug combinations, as well as new uses of existing drugs, are urgently needed to reduce the time required to cure patients with drug-sensitive or multidrug-resistant (MDR) tuberculosis (TB). We compared the sterilizing activity of the standard first-line antitubercular regimen, rifampin-isoniazid-pyrazinamide (RHZ), with that of the novel regimen PA-824–moxifloxacin–pyrazinamide (PaMZ), which is currently being studied in clinical trials (NCT01498419), in the guinea pig model of chronic TB infection, in which animals develop necrotic granulomas histologically r
APA, Harvard, Vancouver, ISO, and other styles
3

Ruzicka, Daniel J., Mayuko Kamakura, Naho Kuroishi, et al. "Characteristics of 2-drug regimen users living with HIV-1 in a real-world setting: A large-scale medical claim database analysis in Japan." PLOS ONE 17, no. 6 (2022): e0269779. http://dx.doi.org/10.1371/journal.pone.0269779.

Full text
Abstract:
Background Regimen simplification to 2-drug antiretroviral therapy (2-ART) may address potential tolerability issues, increase adherence, and reduce toxicity and potential drug-drug-interactions among people living with HIV-1 (PLWH). However, real-world treatment patterns and characteristics of 2-ART users are unclear. Methods This retrospective observational cohort study employed a large-scale medical claim database of Japanese hospitals to extract data on 4,293 PLWH aged ≥18 years with diagnosis of HIV and treated with any ART regimens between April 2008 and April 2019. A 2-ART cohort was co
APA, Harvard, Vancouver, ISO, and other styles
4

Maggiolo, Franco, Nicola Gianotti, Laura Comi, et al. "Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trial." Antiviral Therapy 26, no. 3-5 (2021): 51–57. http://dx.doi.org/10.1177/13596535211042226.

Full text
Abstract:
Background Primary analysis at 24 weeks showed that switching to rilpivirine plus darunavir/cobicistat was non-inferior to continuing a standard three-drug antiretroviral regimen in virologically suppressed people with HIV. We present efficacy and safety data from the 48-week analysis. Methods PROBE 2 is a randomized, open-label trial. Adults who were on a three-drug therapy and had had <50 HIV-1 RNA copies/mL for at least 6 months were randomly assigned (1:1) to 25 mg rilpivirine plus 800/150 darunavir/cobicistat once daily (early switch group) or to continue their regimen for 24 weeks bef
APA, Harvard, Vancouver, ISO, and other styles
5

Sleeper, Rebecca B. "Antipsychotic Dose-Sparing Effect with Addition of Memantine." Annals of Pharmacotherapy 39, no. 9 (2005): 1573–76. http://dx.doi.org/10.1345/aph.1g207.

Full text
Abstract:
OBJECTIVE: To describe a case of an antipsychotic-sparing effect achieved after the addition of memantine to the regimen of a patient with severe Alzheimer's disease and aggressive behavioral disturbances. CASE SUMMARY: A 78-year-old white man with severe Alzheimer's disease was receiving risperidone 2 mg 3 times daily for persistent aggressive and dangerous behavioral disturbances. Memantine was initiated, and the dose was titrated to 10 mg twice daily. The patient's response included improvement in functional status and resolution of problematic behaviors, allowing repeated reduction of the
APA, Harvard, Vancouver, ISO, and other styles
6

Tiberi, Simon, Marie-Christine Payen, Giovanni Sotgiu, et al. "Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB." European Respiratory Journal 47, no. 4 (2016): 1235–43. http://dx.doi.org/10.1183/13993003.02146-2015.

Full text
Abstract:
No large study has ever evaluated the efficacy, safety and tolerability of meropenem/clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to evaluate the therapeutic contribution, effectiveness, safety and tolerability profile of meropenem/clavulanate added to a background regimen when treating MDR- and XDR-TB cases.Patients treated with a meropenem/clavulanate-containing regimen (n=96) showed a greater drug resistance profile than those exposed to a meropenem/clavulanate-sparing regimen (n=168): in the former gr
APA, Harvard, Vancouver, ISO, and other styles
7

Fischl, Margaret A., Ann C. Collier, A. Lisa Mukherjee, et al. "Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen." AIDS 21, no. 3 (2007): 325–33. http://dx.doi.org/10.1097/qad.0b013e328011ddfa.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Karoney, Mercy Jelagat, Mathew Kirtptonui Koech, Evangeline Wawira Njiru, and Willis Dixon Owino Ong’or. "Proximal tubular renal dysfunction among HIV infected patients on Tenofovir versus Tenofovir sparing regimen in western Kenya." PLOS ONE 17, no. 9 (2022): e0273183. http://dx.doi.org/10.1371/journal.pone.0273183.

Full text
Abstract:
Introduction Tenofovir Disoproxil Fumarate (TDF) is the most widely used Anti-Retroviral Therapy (ART) drug due to its potency, safety profile and World Health Organization (WHO) recommendation. TDF causes proximal tubular renal dysfunction (PTRD) leading to Fanconi syndrome, acute kidney injury and chronic kidney disease. Modest rates (2–4%) of TDF related toxicity based on estimated Glomerular Filtration Rate (GFR) have been described, while TDF-induced PTRD has been reported to be 22%. TDF toxicity is more likely among African patients, it is reversible and TDF may be renal dosed in patient
APA, Harvard, Vancouver, ISO, and other styles
9

Stürmer, Martin, Schlomo Staszewski, and Hans Wilhelm Doerr. "Quadruple Nucleoside Therapy with Zidovudine, Lamivudine, Abacavir and Tenofovir in the Treatment of HIV." Antiviral Therapy 12, no. 5 (2007): 695–704. http://dx.doi.org/10.1177/135965350701200514.

Full text
Abstract:
Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality in HIV-infected patients. However, problems such as short-term or long-term toxicity and the development of drug resistance could necessitate a change in the therapy regimen. Whereas various HAART options with low pill burden and favourable long-term tolerability profiles are available for naive patients, treatment of experienced patients tends to be more complex and remains a challenge. Treatment with class sparing nucleoside-only regimens could be an option in this context, but the combination of z
APA, Harvard, Vancouver, ISO, and other styles
10

Kovalskaya, Galina N., Dina Y. Zhukova, and Ekaterina N. Mikhalevich. "Interaction of Drugs Used for the Treatment of Cardiovascular Diseases." Acta Biomedica Scientifica 4, no. 1 (2019): 36–42. http://dx.doi.org/10.29413/abs.2019-4.1.6.

Full text
Abstract:
Combined therapy in cardiology is currently the most recognized method of treatment, especially in patients with hypertension. Approximately in 50 % of patients with hypertension, monotherapy is effective. However to achieve the desired effect in the remaining half of patients, simultaneous administration of two and sometimes three drugs is required. Numerous drugs with a fixed combination of two (and even three) antihypertensive drugs, often used in clinical practice, greatly simplify the dosage regimen of drugs and improve patients’ adherence to treatment. Unfortunately, simultaneous prescri
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Drug-sparing regimen"

1

Papot, Emmanuelle. "Coût des traitements antirétroviraux : évaluation de l’impact d’interventions au niveau des prescripteurs et des patients : ANRS-GOTA : Gestion Optimale des Traitements Antirétroviraux." Electronic Thesis or Diss., Université Paris Cité, 2021. http://www.theses.fr/2021UNIP5253.

Full text
Abstract:
Objectifs : L’objectif principal de ce projet était d’évaluer l’impact d’une série d’interventions, auprès des prescripteurs, et des patients, quant aux dépenses de prescriptions en antirétroviraux (ARV) dans le Service des Maladies Infectieuses et Tropicales (SMIT) de l’Hôpital Bichat, Paris, France. Les objectifs secondaires incluaient la description des combinaisons thérapeutiques utilisées, leur prix, l’évaluation des connaissances, des croyances et représentations des prescripteurs et des personnes vivant avec le VIH (PVVIH) sur le prix des traitements ARV, et de l’acceptabilité de telles
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Drug-sparing regimen"

1

Harper, Lorraine, and David Jayne. The patient with vasculitis. Edited by Giuseppe Remuzzi. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0160.

Full text
Abstract:
The goals of treatment in renal vasculitis are to stop vasculitic activity and recover renal function. Subsequent strategies are required to prevent vasculitis returning and to address longer-term co-morbidities caused by tissue damage, drug toxicity, and increased cardiovascular and malignancy risk.Cyclophosphamide and high-dose glucocorticoids remain the standard induction therapy with alternative immunosuppressives, such as azathioprine, to prevent relapse. Plasma exchange improves renal recovery in severe presentations. Refractory disease resulting from a failure of induction or remission
APA, Harvard, Vancouver, ISO, and other styles
2

Jayne, David. Treatment of ANCA-associated vasculitis. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0132.

Full text
Abstract:
The goals of treatment in anti-neutrophil cytoplasm antibody (ANCA) vasculitis are to stop vasculitic activity, to prevent vasculitis returning, and to address longer-term comorbidities caused by tissue damage, drug toxicity, and increased cardiovascular and malignancy risk. Cyclophosphamide and high-dose glucocorticoids remain the standard induction therapy with alternative immunosuppressives, such as methotrexate or azathioprine, to prevent relapse. Refractory disease resulting from a failure of induction or remission maintenance therapy requires alternative agents and rituximab has been par
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Drug-sparing regimen"

1

Pappas, Peter G. "Fungal Infections in Solid Organ Transplant Recipients." In Clinical Mycology. Oxford University PressNew York, NY, 2003. http://dx.doi.org/10.1093/oso/9780195148091.003.0031.

Full text
Abstract:
Abstract Solid organ transplantation has become an effective life-sparing modality for thousands of patients with organ failure syndromes. In spite of important advances in surgical technique and immunosuppressive regimens that have made solid organ transplantation a safer procedure today when compared to previous decades, there remain substantial risks of infection and other complications related to the procedure. Among the infectious complications of organ transplantation, none is associated with a greater impact on morbidity and mortality than invasive fungal infections (IFI) (Paya, 1993; H
APA, Harvard, Vancouver, ISO, and other styles
2

Jayne, David. "Treatment of ANCA-associated vasculitis." In Oxford Textbook of Rheumatology. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0132_update_001.

Full text
Abstract:
The goals of treatment in anti-neutrophil cytoplasm antibody (ANCA) vasculitis are to stop vasculitic activity, to prevent vasculitis returning, and to address longer-term comorbidities caused by tissue damage, drug toxicity, and increased cardiovascular and malignancy risk. Cyclophosphamide and high-dose glucocorticoids remain the standard induction therapy with alternative immunosuppressives, such as methotrexate or azathioprine, to prevent relapse. Refractory disease resulting from a failure of induction or remission maintenance therapy requires alternative agents and rituximab has been par
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Drug-sparing regimen' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography